SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions around market downturns, potential support levels, and the influence of macroeconomic factors. Community members are debating whether this is a buying opportunity or the start of a deeper correction, while also considering the impact of potential government actions and large liquidations. Some traders are pointing to technical indicators and historical patterns to predict future price movements.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as community members discuss its potential to be the next PEPE, with many highlighting its availability on the Solana blockchain via Phantom Wallet. The coin is experiencing increased attention and bullish sentiment, with some suggesting it's gearing up for a significant breakout.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending due to increased community interest following a recent mention on Jim Cramer's Mad Money, highlighting potential FDA approval of their epinephrine sublingual film, Anaphylm. The community is actively discussing the positive implications of the Cramer mention, the potential for a squeeze, and the possible competitive advantages over existing treatments like EpiPen and Neffy. Some caution against the Cramer effect while others celebrate the increased awareness for AQST.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Fueled by positive clinical trial results for its oral acromegaly treatment, CRNX is trending as traders discuss the potential for a short squeeze given high short interest and substantial institutional ownership. The community is closely watching for the offering to close and debating its impact on the stock's price action, with some anticipating a continued rise while others foresee a pullback. Bullish sentiment is supported by analysts' optimistic revenue projections, while bears point to the company's financials and insider selling.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending as the community rallies around the meme-based token, expressing bullish sentiment and encouraging others to join. The community is actively promoting the token and celebrating its trending status, with some highlighting support from notable investors. Discussions revolve around community strength and the potential for significant growth.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss the potential impact of tariffs and the company's existing and expanding manufacturing presence in the U.S., particularly in North Carolina, which could provide a competitive advantage. The potential approval of Wegovy in pill form is also generating excitement, with some predicting it could revolutionize obesity treatment. However, job cuts and competition from other drugs are still risks in play for Novo Nordisk.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

JINGLE.X is trending as community members are actively discussing potential gains and encouraging others to buy, with some mentioning a possible pump. Several are drawing comparisons to other meme coins and touting it as the next opportunity for significant returns. The conversation also includes promotion of related Solana-based tokens, creating a broader buzz within that ecosystem.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending because the community is actively spreading awareness and prompting the question 

Concentrix Corp. engages in the provision of customer experience solutions and technology. The company was founded in 1973 and is headquartered in Newark, CA.

Concentrix Corp.

Concentrix Corporation

Concentrix (CNXC) is trending following an earnings report that included lowered guidance, which has sparked debate among investors regarding a potential overdone sell-off. Community members are weighing whether the stock will rebound or test lower support levels, while also noting a significant short interest that could lead to a squeeze. Despite the negative reaction, some are pointing to the company's low PE ratio as a reason for optimism.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as discussions revolve around rare earth elements and potential price floors being considered by G7 nations to counter China's dominance in the sector. Community members are weighing the potential impacts of government stakes and contracts, drawing comparisons to Lithium Americas, while also speculating on future price targets. Investors are closely monitoring technical indicators and upcoming catalysts, such as earnings and processing capacity increases.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

Equity

AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?

AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

Eli Lilly &amp; Co. (LLY) has halted a study of its drug Bimagrumab, alone or in combination with its approved weight-loss drug Tirzepatide, in patients with obesity.A U.S. registry of clinical trials <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://clinicaltrials.gov/study/NCT06901349">indicates</a> that the study has been terminated due to strategic business reasons without elaboration.The purpose of the study was to see how well and how safely Bimagrumab, Tirzepatide, and the combination worked in lowering body weight in participants with obesity or overweight and type 2 diabetes. Tirzepatide is the active ingredient in the company’s popular obesity drug Zepbound. While the primary goal of the study was weight loss, the company also sought to identify the change in body fat mass associated with the drug.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-25/lilly-halts-diabetes-trial-of-muscle-sparing-drug-with-zepbound">first</a> reported the termination of the trial. Following the development, the stock traded nearly 1% lower in Thursday’s pre-market session.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Lilly closed the mid-stage trial on June 10, after starting it in May, according to the registry. The study had 50 locations in the U.S. and abroad and was supposed to last about 13 months. Lilly gained access to Bimagrumab through its $1.925 billion acquisition of privately held Versanis Bio, which was completed in August 2023.A parallel study in obese patients without diabetes remains active, Bloomberg noted.Eli Lilly <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-s-newest-obesity-drug-candidate-stirs-wall-street-buzz-but-not-everyone-s-sold/chmJdk1RR3q">said</a> in June that patients who took the highest dose of Bimagrumab alongside rival Novo Nordisk’s Semaglutide lost more fat mass than those on Semaglutide alone in a trial.LLY stock is down 4% this year and approximately 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evaxion-stock-makes-whopping-jump-pre-market-after-outlicensing-vaccine-candidate/chDl7l1R34i">Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Terminates A Study Of Bimagrumab In Obesity

A U.S. registry of clinical trials shows that the study has been terminated for strategic business reasons.

LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.

The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement

Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? 

Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR). 

Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the preceding trading day.

Top Analyst Reports for Apple, Eli Lilly & Chevron

Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.

Eli Lilly and Company (LLY) announced on Tuesday that it plans to construct a new $ 6.5 billion manufacturing facility in Texas as part of its efforts to expand domestic medicine production.The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lilly-plans-to-build-a-new-6-5-billion-facility-to-manufacture-active-pharmaceutical-ingredients-in-texas-302563621.html">stated</a> that the Houston facility will be operational within five years and will focus on manufacturing the company's pipeline of small molecule medicines across various therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience. The company also said that the site will be among those that manufacture its much-awaited oral obesity drug Orforglipron. Lilly expects to make regulatory submissions for Orforglipron in the treatment of obesity by the end of this year."Our new Houston site will enhance Lilly's ability to manufacture Orforglipron at scale and, if approved, help fulfill the medicine's potential as a metabolic health treatment for tens of millions of people worldwide who prefer the ease of a pill that can be taken without food and water restrictions," said CEO David A Ricks.According to Lilly, the new facility will bring 615 new high-wage jobs to the Greater Houston area, including engineers, scientists, and lab technicians, in addition to 4,000 construction jobs. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within ‘bearish’ territory while message volume fell from ‘normal’ to ‘low’ levels.In February, Lilly announced its plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the U.S., bringing the company’s total U.S. capital expansion commitments to more than $50 billion since 2020.While three of the facilities will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis, and further strengthening Lilly's supply chain, the fourth will extend the company's global parenteral manufacturing network for future injectable therapies, the company had said.Last week, the company also <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">announced</a> plans for a $5 billion manufacturing facility in Virginia.LLY stock is down 3% this year and approximately 19% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ionis-pharma-stock-rises-after-multiple-price-target-hikes/chDLGmZR35v">Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas

The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LLY News

LLY Lilly(Eli) & Co